Objective
to test the hypothesis that intensified P2Y12-receptor inhibition with prasugrel 60 mg is superior to standard loading dose of clopidogrel 600 mg
Study
multicentre, assessor-blinded randomised trial
Population
patients undergoing elective PCI. After PCI all patients were on clopidogrel 75 mg/day and aspirin
Endpoints
composite of all-cause death, MI, stent thrombosis, stroke or urgent revascularisation at 30 days
Conclusion
intensified P2Y12-receptor inhibition was associated with similar adverse event rate compared to standard loading dose clopidogrel in patients with elective PCI. Caution: prematurely terminated
Mehilli et al. Circulation Cardiovascular Interventions. 2020 June 13:e008649